Pathology: Acute Spinal Cord Injury (ASCI) Therapeutics

• Publication date: May 2012
• Report size: 65 pages

GlobalData, the market analysis specialist, has released its new report, “”. The report is an essential source of information and analysis on the global Acute Spinal Cord Injury Therapeutics industry . The report identifies the major industry developments shaping and driving the global Acute Spinal Cord Injury Therapeutics industry . The report also provides insights on the prevalent competitive landscape and the emerging players exp...

GlobalData, the market analysis specialist, has released its new report, “”. The report is an essential source of information and analysis on the global Acute Spinal Cord Injury Therapeutics industry . The report identifies the major industry developments shaping and driving the global Acute Spinal Cord Injury Therapeutics industry . The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the industry positioning of the current industry leaders. Most importantly, the report provides valuable insights on the new product development within the global Acute Spinal Cord Injury Therapeutics segment . This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Industry expert's team of market experts.

Scope of the Research

The report provides data on the key drivers and challenges of the Acute Spinal Cord Injury Therapeutics industry . Its scope includes -
- Annualized seven key industry s (US, France, Germany, Italy, Spain, UK and Japan) Acute Spinal Cord Injury Therapeutics industry revenues data 2005-2009, projection for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key industry s. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Acute Spinal Cord Injury Therapeutics industry .
- Insightful review of the key market drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, industry characterization, unmet needs and the implications for the Acute Spinal Cord Injury Therapeutics therapeutics industry .
- Analysis of key recent licensing and partnership agreements in Acute Spinal Cord Injury Therapeutics industry

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of new product development and technologies and by identifying the industry players with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Acute Spinal Cord Injury Therapeutics industry .
- Drive revenues by understanding the major industry developments, innovative products and technologies, industry sectors and industry players likely to impact the global Acute Spinal Cord Injury Therapeutics industry in future.
- Formulate effective sales and industry ing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and industry ing efforts by identifying the industry categories and sectors that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Acute Spinal Cord Injury Therapeutics industry landscape? – Identify, understand and decide.

Therapy Industry in Europe

1 Table of contents

I Table of contents 3
I. 1 List of Data tables 5
I. 2 List of Charts 6

II Acute SCI Therapeutics: Introduction 7
II. 1 Disease Data 7
II. 2 Epidemiology 8
II. 3 Etiology 9
II. 4 Effects of SCI 10
II. 5 Signs and Symptoms 11
II. 6 Diagnosis 12
II. 7 Treatment and Management Pattern 13
II. 8 Referral Pathway 14
II. 9 GlobalData Pipeline Report Guidance 15

III Acute SCI Therapeutics: March ket Characterization 16
III. 1 Overview 16
III. 2 Acute SCI Therapeutics March ket Size (2005–2010) – World 16
III. 3 Acute SCI Therapeutics March ket Forecasted data (2010–2017) – World 17
III. 4 Acute SCI Therapeutics March ket Size (2005–2010) – The US 18
III. 5 Acute SCI Therapeutics March ket Forecasted data (2010–2017) – The US 19
III. 6 Acute SCI Therapeutics March ket Size (2005–2010) – France 20
III. 7 Acute SCI Therapeutics March ket Forecasted data (2010–2017) – France 21
III. 8 Acute SCI Therapeutics March ket Size (2005–2010) – Germany 22
III. 9 Acute SCI Therapeutics March ket Forecasted data (2010-2017) – Germany 23
III. 10 Acute SCI Therapeutics March ket Size (2005–2010) – Italy 24
III. 11 Acute SCI Therapeutics March ket Forecasted data (2010–2017) – Italy 25
III. 12 Acute SCI Therapeutics March ket Size (2005–2010) – Spain 26
III. 13 Acute SCI Therapeutics March ket Forecasted data (2010–2017) – Spain 27
III. 14 Acute SCI Therapeutics March ket Size (2005–2010) – The UK 28
III. 15 Acute SCI Therapeutics March ket Forecasted data (2010–2017) – The UK 29
III. 16 Acute SCI Therapeutics March ket Size (2005–2010) – Japan 30
III. 17 Acute SCI Therapeutics March ket Forecasted data (2010–2017) – Japan 31
III. 18 Drivers and Barriers for the Acute SCI Therapeutics March ket 32
III. 18.1 Drivers for the Acute SCI Therapeutics March ket 32
III. 18.2 Barriers for Acute SCI Therapeutics March ket 32
III. 19 Opportunity and Unmet Need Analysis 33
III. 19.1 Opportunity and Unmet Need in the Acute SCI March ket 33
III. 20 Key Takeaway 33

IV Acute SCI Therapeutics: Competitive Assessment 34
IV. 1 Overview 34
IV. 2 Strategic Competitor Assessment 34
IV. 3 Product Profile for the Major March keted Products in the Acute SCI Therapeutics 35
IV. 3.1 Medrol 35
IV. 4 Key Takeaway 35

V Acute SCI Therapeutics: Pipeline Assessment 36
V. 1 Overview 36
V. 2 Strategic Pipeline Assessment 36
V. 3 Acute SCI Therapeutics Pipeline – Pipeline by Phases of Development 36
V. 3.1 Acute SCI Therapeutics – Phase III Pipeline 37
V. 3.2 Acute SCI Therapeutics –Phase II Pipeline 37
V. 3.3 Acute SCI Therapeutics –Phase I Pipeline 37
V. 3.4 Acute SCI Therapeutics – Preclinical Phase 37
V. 3.5 Acute SCI Therapeutics – Discovery Pipeline 38
V. 4 Technology Trends Analytic Framework 38
V. 5 Acute SCI Therapeutics March ket – Pipeline by Mechanism of Action 40
V. 6 Acute SCI Therapeutics – Promising Drugs under Clinical Development 40
V. 7 Molecule Profiling for Promising Drugs Under Clinical Development 41
V. 7.1 Lyrica 41
V. 7.2 ProCord 42
V. 8 Key Takeaway 42

VI Acute SCI Therapeutics: Clinical Trials Mapping 43
VI. 1 Clinical Trials by Country 43
VI. 2 Clinical Trials by Phase 44
VI. 3 Clinical Trials by Trial Status 45
VI. 4 Top 10 Firms Participating in Therapeutics Clinical Trials 46
VI. 5 Key Sponsors 47

VII Acute SCI Therapeutics: Strategic Assessment 49
VII. 1 Key Events Impacting the Future March ket 49
VII. 2 Implications for Future March ket Competition 50

VIII Acute SCI Therapeutics: Future Players 51
VIII. 1 Introduction 51
VIII. 2 Firms Profiles 51
VIII. 2.1 Pfizer 51
VIII. 2.2 Proneuron Biotechnologies 56

IX Acute SCI Therapeuctics: Licensing and Partnership Deals 57

X Acute SCI Therapeutics: Appendix 58
X. 1 March ket Definitions 58
X. 2 Abbreviations 58
X. 3 Research Methodology 59
X. 3.1 Coverage 59
X. 3.2 Secondary Research 59
X. 3.3 Forecasted data ing 60
X. 3.4 Primary Research 63
X. 3.5 Expert Panel Validation 63
X. 4 Contact Us 63
X. 5 Disclaimer 63
X. 6 Bibliography 64

1.1

List of Tables


Data table 1: Effects of SCI by Location 10
Data table 2: Spinal Injury Impairment Scale 12
Data table 3: Acute SCI Therapeutics March ket, Global, Sales, (USD Million), 2005–2010 16
Data table 4: Acute SCI Therapeutics March ket, Global, Forecasted data (USD Million), 2010–2017 17
Data table 5: Acute SCI Therapeutics March ket, The US, Sales (USD Million), 2005–2010 18
Data table 6: Acute SCI Therapeutics March ket, The US, Forecasted data (USD Million), 2010–2017 19
Data table 7: Acute SCI Therapeutics March ket, France, Sales (USD Million), 2005–2010 20
Data table 8: Acute SCI Therapeutics March ket, France, Forecasted data s (USD Million), 2010–2017 21
Data table 9: Acute SCI Therapeutics March ket, Germany, Sales (USD Million), 2005–2010 22
Data table 10: Acute SCI Therapeutics March ket, Germany, Forecasted data (USD Million), 2010–2017 23
Data table 11: Acute SCI Therapeutics March ket, Italy, Sales (USD Million), 2005–2010 24
Data table 12: Acute SCI Therapeutics March ket, Italy, Forecasted data (USD Million), 2010–2017 25
Data table 13: Acute SCI Therapeutics March ket, Spain, Sales (USD Million), 2005–2010 26
Data table 14: Acute SCI Therapeutics March ket, Spain, Forecasted data (USD Million), 2010–2017 27
Data table 15: Acute SCI Therapeutics March ket, The UK, Sales (USD Million), 2005–2010 28
Data table 16: Acute SCI Therapeutics March ket, The UK, Forecasted data (USD Million), 2010–2017 29
Data table 17: Acute SCI Therapeutics March ket, Japan, Sales (USD Million), 2005–2010 30
Data table 18: Acute SCI Therapeutics March ket, Japan, Forecasted data (USD Million), 2010–2017 31
Data table 19: Acute SCI Therapeutics – Phase III Clinical Pipeline, 2011 37
Data table 20: Acute SCI Therapeutics – Phase II Clinical Pipeline, 2011 37
Data table 21: Acute SCI Therapeutics – Phase I Clinical Pipeline, 2011 37
Data table 22: Acute SCI Therapeutics – Preclinical Pipeline, 2011 37
Data table 23: Acute SCI Therapeutics – Discovery Pipeline, 2011 38
Data table 24: Acute SCI Therapeutics – Most Promising Drugs Under Clinical Development, 2011 40
Data table 25: Acute SCI Therapeutics March ket, Clinical Trials by Country, 2011 43
Data table 26: Acute SCI Therapeutics March ket, Clinical Trials by Phase, 2011 44
Data table 27: Acute SCI Therapeutics March ket, Clinical Trials by Trial Status, 2011 45
Data table 28: Acute SCI Therapeutics March ket, Clinical Trials by Top Firms Participating in Therapeutics Clinical Trials, 2011 46
Data table 29: Acute SCI Therapeutics March ket – Clinical Trials by Overall Sponsors, 2011 47
Data table 30: Acute SCI Therapeutics March ket – Clinical Trials by Key Sponsors, 2011 48
Data table 31: Pfizer, CNS Pipeline, As on February ruary 28, 2011 54
Data table 32: Pfizer, SCI Pipeline, February ruary 28, 2011 54
Data table 33: Pfizer, Deals, from 2009 to 2010 55
Data table 34: NeuroHealing Pharmaceuticals – CNS Pipeline Products, 2011 56
Data table 35: SCI Therapeutics March ket, Global, Deals, from 2007 to 2008 57

1.2

List of Figures


Chart 1: Spinal Cord After Injury 8
Chart 2: Acute SCI Therapeutics March ket – SCI Causes 9
Chart 3: Effects of SCIs 10
Chart 4: Referral Pathway for Acute SCI 14
Chart 5: Acute SCI Therapeutics March ket, Global, Sales (USD Million), 2005–2010 16
Chart 6: Acute SCI Therapeutics March ket, Global, Forecasted data (USD Million), 2010–2017 17
Chart 7: Acute SCI Therapeutics March ket, The US, Sales (USD Million), 2005–2010 18
Chart 8: Acute SCI Therapeutics March ket, The US, Forecasted data (USD Million), 2010–2017 19
Chart 9: Acute SCI Therapeutics March ket, France, Sales (USD Million), 2005–2010 20
Chart 10: Acute SCI Therapeutics March ket, France, Forecasted data (USD Million), 2010–2017 21
Chart 11: Acute SCI Therapeutics March ket, Germany, Sales (USD Million), 2005–2010 22
Chart 12: Acute SCI Therapeutics March ket, Germany, Forecasted data (USD Million), 2010–2017 23
Chart 13: Acute SCI Therapeutics March ket, Italy, Sales (USD Million), 2005–2010 24
Chart 14: Acute SCI Therapeutics March ket, Italy, Forecasted data (USD Million), 2010–2017 25
Chart 15: Acute SCI Therapeutics March ket, Spain, Sales (USD Million), 2005–2010 26
Chart 16: Acute SCI Therapeutics March ket, Spain, Forecasted data (USD Million), 2010–2017 27
Chart 17: Acute SCI Therapeutics March ket, The UK, Sales (USD Million), 2005–2010 28
Chart 18: Acute SCI Therapeutics March ket, The UK, Forecasted data (USD Million), 2010–2017 29
Chart 19: Acute SCI Therapeutics March ket, Japan, Sales (USD Million), 2005–2010 30
Chart 20: Acute SCI Therapeutics March ket, Japan, Forecasted data (USD Million), 2010–2017 31
Chart 21: Opportunity and Unmet Need in the Acute SCI Therapeutics March ket, 2010 33
Chart 22: Strategic Competitor Assessment of the March keted Products for Acute SCIs, 2011 34
Chart 23: Acute SCI Therapeutics Pipeline by Phase of Development, 2011 36
Chart 24: Technology Trends Analytic Framework of the Acute SCI Therapeutics Pipeline, 2011 38
Chart 25: Technology Trends Analytic Framework of the Acute SCI Therapeutics Pipeline- Description, 2011 39
Chart 26: Acute SCI Therapeutics, Pipeline by Mechanism of Action, 2011 40
Chart 27: Acute SCI Therapeutics March ket, Clinical Trials by Country, 2011 43
Chart 28: Acute SCI Therapeutics March ket – Clinical Pipeline by Phase, 2011 44
Chart 29: Acute SCI Therapeutics March ket – Clinical Trials by Trial Status, 2011 45
Chart 30: Acute SCI Therapeutics March ket – Clinical Trials by Top Firms Participating in Therapeutics Clinical Trials, 2011 46
Chart 31: Acute SCI Therapeutics March ket – Clinical Trials by Overall Sponsors, 2011 47
Chart 32: Acute SCI Therapeutics March ket – Clinical Trials by Key Sponsors, 2011 48
Chart 33: Acute SCI Therapeutics, Global, Key Events Impacting the Future March ket 49
Chart 34: Implications for Future March ket Competition in the Acute SCI Therapeutics March ket, 2011 50
Chart 35: Acute SCI Therapeutics March ket – Clinical Pipeline by Firms, 2011 51
Chart 36: GlobalData March ket Forecasted data ing Model 62

Companies Mentioned
Pfizer
Proneuron Biotechnologies